Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

40.0%

4 terminated/withdrawn out of 10 trials

Success Rate

42.9%

-43.6% vs industry average

Late-Stage Pipeline

20%

2 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A

5(55.6%)

Phase 2

2(22.2%)

Phase 4

1(11.1%)

Phase 3

1(11.1%)

9Total

N/A(5)

Phase 2(2)

Phase 4(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT03113994Phase 2Terminated

Statin Monotherapy for Treatment of Endocrine Metabolic Disease Risk

Role: collaborator

NCT03111030Not ApplicableCompleted

ProACTIVE SCI Physical Activity Intervention

Role: collaborator

NCT03911492Not ApplicableUnknown

Canadian-American Spinal Cord Perfusion Pressure and Biomarker Study

Role: collaborator

NCT04493606Not ApplicableUnknown

Implementation of the ProACTIVE Toolkit in the Hospital and Community Setting

Role: collaborator

NCT01597518Phase 2Terminated

Riluzole in Spinal Cord Injury Study

Role: collaborator

NCT01279811Not ApplicableCompleted

The Canadian Multicentre CSF Monitoring and Biomarker Study

Role: collaborator

NCT02298660Phase 4Completed

Botox for Neurogenic Detrusor Overactivity and the Prevention of Autonomic Dysreflexia Following SCI

Role: lead

NCT02799966Not ApplicableTerminated

Recovery of Upper Limb Function in Persons With Spinal Cord Injury: Lead-In Study

Role: collaborator

NCT02861612Withdrawn

Nerve Transfers to Restore Hand Function in Spinal Cord Injury

Role: collaborator

NCT01828203Phase 3Unknown

Minocycline in Acute Spinal Cord Injury (MASC)

Role: lead

All 10 trials loaded